Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- Prevalence of polypharmacy
研究概览
简要总结
As the proportion of elderly population increasing over the last years, polypharmacy and drug-drug interactions (DDI) has been a common health care problem. This study will be performed to find out to prevalence of polypharmacy, inappropriate drug use and DDIs in in elderly patients presenting to a outpatient cardiology clinics.
详细描述
Objective:
As the proportion of elderly population increasing over the last years, polypharmacy and drug-drug interactions (DDI) has been a common health care problem. However, very limited epidemiologic data are available describing polypharmacy, potentially DDIs, and potentially inappropriate medications and their consequences in elderly Turkish patients. Therefore, this study will be performed to find out to prevalence of polypharmacy, inappropriate drug use and DDIs in elderly patients presenting to a outpatient cardiology clinics.
Methods:
The EPIC (Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients) study will be the first large-scale, observational, real-world multicenter study to evaluate DDIs ve polypharmacy in elderly cardiac outpatients conducted in Turkey. We will enroll all consecutive patients (aged≥ 65 years) admitted to the outpatient cardiology clinics from January 30, 2018, through June 30, 2018, provided written informed consent. Approximately 5000 patients will be enrolled in this non-interventional study. All the data will be collected at one point in time and current clinical practice will be evaluated.
Results:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All consecutive patients with aged ≥ 65 years
排除标准
- •Patients under 65 years of age
- •Patients who do not want to participate in our study
结局指标
主要结局
Prevalence of polypharmacy
时间窗: 6 months
Polypharmacy will be defined as being on five or more medications at one time.
Severity of comorbid diseases
时间窗: 6 months
The severity of comorbid diseases will be recorded and scored according to Charlson comorbidity index (CCI) and patients will be divided into three groups: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores ≥5.
Drug-drug interactions
时间窗: 6 months
DDIs will be checked with Lexicomp®. Severe drug interactions will be defined with category D or X DIs.
Prevalence of inappropriate medications
时间窗: 6 months
Potentially inappropriate medications will be defined with 2015 update of Beers criteria.
次要结局
未报告次要终点
研究者
EDA ÖZLEK
Faculty of Medicine, Department of Cardiology, M.D., Principal Investigator
Muğla Sıtkı Koçman University